XML 90 R41.htm IDEA: XBRL DOCUMENT
v3.19.3

Segments (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2019
Summary of Segment Profit | a. Segment information:
|  | Three months ended September 30, 2019 |
|  | North America |  |  | Europe |  |  | International Markets |
|  | (U.S. $ in millions) |
Revenues |  | $ | 2,051 |  |  | $ | 1,163 |  |  | $ | 736 |
Gross profit |  |  | 1,048 |  |  |  | 662 |  |  |  | 295 |
R&D expenses |  |  | 156 |  |  |  | 63 |  |  |  | 21 |
S&M expenses |  |  | 219 |  |  |  | 206 |  |  |  | 114 |
G&A expenses |  |  | 112 |  |  |  | 56 |  |  |  | 32 |
Other income |  |  | (5 | ) |  |  | (4 | ) |  |  | (1 | )
Segment profit |  | $ | 565 |  |  | $ | 341 |  |  | $ | 130 |
|  | Three months ended September 30 , 2018 |
|  | North America |  |  | Europe |  |  | International Markets |
|  | (U.S. $ in millions) |
Revenues |  | $ | 2,265 |  |  | $ | 1,212 |  |  | $ | 726 |
Gross profit |  |  | 1,196 |  |  |  | 676 |  |  |  | 301 |
R&D expenses |  |  | 158 |  |  |  | 62 |  |  |  | 21 |
S&M expenses |  |  | 265 |  |  |  | 242 |  |  |  | 120 |
G&A expenses |  |  | 128 |  |  |  | 74 |  |  |  | 37 |
Other (income) expense |  |  | (4 | ) |  |  | 1 |  |  |  | — |
Segment profit |  | $ | 649 |  |  | $ | 297 |  |  | $ | 123 |
|  | Nine months ended September 30, 2019 |
|  | North America |  |  | Europe |  |  | International Markets |
|  | (U.S. $ in millions) |
Revenues |  | $ | 6,169 |  |  | $ | 3,611 |  |  | $ | 2,145 |
Gross profit |  |  | 3,155 |  |  |  | 2,066 |  |  |  | 877 |
R&D expenses |  |  | 497 |  |  |  | 199 |  |  |  | 66 |
S&M expenses |  |  | 756 |  |  |  | 637 |  |  |  | 348 |
G&A expenses |  |  | 342 |  |  |  | 175 |  |  |  | 102 |
Other income |  |  | (6 | ) |  |  | (5 | ) |  |  | (2 | )
Segment profit |  | $ | 1,566 |  |  | $ | 1,060 |  |  | $ | 363 |
|  | Nine months ended September 30, 2018 |
|  | North America |  |  | Europe |  |  | International Markets |
|  | (U.S. $ in millions) |
Revenues |  | $ | 7,059 |  |  | $ | 3,982 |  |  | $ | 2,265 |
Gross profit |  |  | 3,778 |  |  |  | 2,195 |  |  |  | 942 |
R&D expenses |  |  | 528 |  |  |  | 208 |  |  |  | 70 |
S&M expenses |  |  | 813 |  |  |  | 725 |  |  |  | 384 |
G&A expenses |  |  | 357 |  |  |  | 243 |  |  |  | 115 |
Other income |  |  | (206 | ) |  |  | (1 | ) |  |  | (11 | )
Segment profit |  | $ | 2,286 |  |  | $ | 1,020 |  |  | $ | 384 |
Schedule Of Consolidated Income Before Income Tax |
|  | Three months ended |  |  | Nine months ended |
|  | September 30, |  |  | September 30, |
|  | 2019 |  |  | 2018 |  |  | 2019 |  |  | 2018 |
|  | (U.S. $ in millions) |  |  | (U.S. $ in millions) |
North America profit |  | $ | 565 |  |  | $ | 649 |  |  | $ | 1,566 |  |  | $ | 2,286 |
Europe profit |  |  | 341 |  |  |  | 297 |  |  |  | 1,060 |  |  |  | 1,020 |
International Markets profit |  |  | 130 |  |  |  | 123 |  |  |  | 363 |  |  |  | 384 |
Total segment s profit |  |  | 1,036 |  |  |  | 1,069 |  |  |  | 2,989 |  |  |  | 3,690 |
Profit of other activities |  |  | 16 |  |  |  | 35 |  |  |  | 92 |  |  |  | 87 |
|  |  | 1,051 |  |  |  | 1,104 |  |  |  | 3,081 |  |  |  | 3,777 |
Amounts not allocated to segments: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Amortization |  |  | 255 |  |  |  | 297 |  |  |  | 823 |  |  |  | 909 |
Other assets impairments, restructuring and other items |  |  | 160 |  |  |  | 139 |  |  |  | 263 |  |  |  | 834 |
Goodwill impairment |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 300 |
Intangible asset impairments |  |  | 177 |  |  |  | 519 |  |  |  | 1,206 |  |  |  | 1,246 |
G ain on divestitures, net of divestitures related costs |  |  | (3 | ) |  |  | (31 | ) |  |  | (12 | ) |  |  | (114 | )
Other R&D expenses (income) |  |  | (7 | ) |  |  | 60 |  |  |  | (7 | ) |  |  | 82 |
Costs related to regulatory actions taken in facilities |  |  | 11 |  |  |  | 1 |  |  |  | 28 |  |  |  | 6 |
Legal settlements and loss contingencies |  |  | 468 |  |  |  | 19 |  |  |  | 1,171 |  |  |  | (1,239 | )
Other unallocated amounts |  |  | 72 |  |  |  | 84 |  |  |  | 201 |  |  |  | 226 |
Consolidated operating income (loss) |  |  | (81 | ) |  |  | 16 |  |  |  | (591 | ) |  |  | 1,527 |
Financial expenses, net |  |  | 211 |  |  |  | 229 |  |  |  | 635 |  |  |  | 736 |
Consolidated income (loss) before income taxes |  | $ | (292 | ) |  | $ | (213 | ) |  | $ | (1,226 | ) |  | $ | 791 |
Schedule of Net Sales by Product Line | b. Segment revenues by major products and activities: The following tables present revenues by major products and activities for the three months and the nine months ended September 30, 2019 and 2018:
|  | Three months ended September 30, |
|  | 2019 |  |  | 2018 |
|  | (U.S. $ in millions) |
No rth Ameri ca |  |  |  |  |  |  |  |
Generic products |  | $ | 914 |  |  | $ | 922 |
COPAXONE |  |  | 271 |  |  |  | 463 |
BENDEKA/TREANDA |  |  | 124 |  |  |  | 161 |
ProAir* |  |  | 71 |  |  |  | 107 |
QVAR |  |  | 60 |  |  |  | 36 |
AJOVY |  |  | 25 |  |  |  | — |
AUSTEDO |  |  | 105 |  |  |  | 62 |
Anda |  |  | 351 |  |  |  | 333 |
Other |  |  | 131 |  |  |  | 182 |
Total |  | $ | 2,051 |  |  | $ | 2,265 |
* | Does not include sales of ProAir authorized generic, which are included under generics products.
|  | Nine months ended September 30, |
|  | 2019 |  |  | 2018 |
|  | (U.S. $ in millions) |
North America |  |  |  |  |  |  |  |
Generic products |  | $ | 2,826 |  |  | $ | 2,957 |
COPAXONE |  |  | 753 |  |  |  | 1,403 |
BENDEKA/TREANDA |  |  | 353 |  |  |  | 502 |
ProAir* |  |  | 194 |  |  |  | 352 |
QVAR |  |  | 183 |  |  |  | 173 |
AJOVY |  |  | 68 |  |  |  | — |
AUSTEDO |  |  | 276 |  |  |  | 136 |
Anda |  |  | 1,080 |  |  |  | 984 |
Other |  |  | 436 |  |  |  | 554 |
Total |  | $ | 6,169 |  |  | $ | 7,059 |
* | Does not include sales of ProAir authorized generic, which are included under generics products.
|  | Three months ended September 30, |
|  | 2019 |  |  | 2018 |
|  | (U.S. $ in millions) |
Europe |  |  |  |  |  |  |  |
Generic products |  | $ | 836 |  |  | $ | 845 |
COPAXONE |  |  | 106 |  |  |  | 124 |
Respiratory products |  |  | 87 |  |  |  | 93 |
Other |  |  | 134 |  |  |  | 150 |
Total |  | $ | 1,163 |  |  | $ | 1,212 |
|  | Nine months ended September 30, |
|  | 2019 |  |  | 2018 |
|  | (U.S. $ in millions) |
Europe |  |  |  |  |  |  |  |
Generic products |  | $ | 2,599 |  |  | $ | 2,749 |
COPAXONE |  |  | 327 |  |  |  | 417 |
Respiratory products |  |  | 267 |  |  |  | 312 |
Other |  |  | 417 |  |  |  | 504 |
Total |  | $ | 3,611 |  |  | $ | 3,982 |
|  | Three months ended September 30, |
|  | 2019 |  |  | 2018 |
|  | (U.S. $ in millions) |
International markets |  |  |  |  |  |  |  |
Generic products |  | $ | 474 |  |  | $ | 498 |
COPAXONE |  |  | 20 |  |  |  | 14 |
Distribution |  |  | 176 |  |  |  | 149 |
Other |  |  | 66 |  |  |  | 65 |
Total |  | $ | 736 |  |  | $ | 726 |
|  | Nine months ended September 30, |
|  | 2019 |  |  | 2018 |
|  | (U.S. $ in millions) |
International markets |  |  |  |  |  |  |  |
Generic products |  | $ | 1,404 |  |  | $ | 1,523 |
COPAXONE |  |  | 46 |  |  |  | 52 |
Distribution |  |  | 491 |  |  |  | 456 |
Other |  |  | 204 |  |  |  | 233 |
Total |  | $ | 2,145 |  |  | $ | 2,265 |

X
- Definition Schedule of consolidated income before income tax. + References No definition available. + Details
Name: | teva_ScheduleOfConsolidatedIncomeBeforeIncomeTaxTableTextBlock
Namespace Prefix: | teva_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8924-108599 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8906-108599 + Details
Name: | us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e9031-108599 + Details
Name: | us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration